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Abstract
The RNA response element TAR plays a critical role in HIV replication by providing a binding site for the recruitment of the
viral transactivator protein Tat. Using a structure-guided approach, we have developed a series of conformationally-
constrained cyclic peptides that act as structural mimics of the Tat RNA binding region and block Tat-TAR interactions at
nanomolar concentrations in vitro. Here we show that these compounds block Tat-dependent transcription in cell-free
systems and in cell-based reporter assays. The compounds are also cell permeable, have low toxicity, and inhibit replication
of diverse HIV-1 strains, including both CXCR4-tropic and CCR5-tropic primary HIV-1 isolates of the divergent subtypes A, B,
C, D and CRF01_AE. In human peripheral blood mononuclear cells, the cyclic peptidomimetic L50 exhibited an IC50
,250 nM. Surprisingly, inhibition of LTR-driven HIV-1 transcription could not account for the full antiviral activity. Timed
drug-addition experiments revealed that L-50 has a bi-phasic inhibition curve with the first phase occurring after HIV-1 entry
into the host cell and during the initiation of HIV-1 reverse transcription. The second phase coincides with inhibition of HIV-
1 transcription. Reconstituted reverse transcription assays confirm that HIV-1 (2) strand strong stop DNA synthesis is
blocked by L50-TAR RNA interactions in-vitro. These findings are consistent with genetic evidence that TAR plays critical
roles both during reverse transcription and during HIV gene expression. Our results suggest that antiviral drugs targeting
TAR RNA might be highly effective due to a dual inhibitory mechanism.
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Introduction
Highly active antiretroviral therapy (HAART) has led to a
dramatic increase in the longevity of patients infected with HIV
[1]. Unfortunately, even the most effective therapy does not
completely eradicate the virus and active viral replication resumes
immediately after treatment interruption [2]. The emergence of
drug resistance further complicates antiviral therapy and can lead
to treatment failure [3], underscoring the continuing need to
develop new HIV antivirals with novel targets and mechanisms of
action [4].
Tat, a viral encoded transcriptional activator, and its cellular co-
factor, the transcription elongation factor-b (P-TEFb) are recruited
to the elongating RNA polymerase II (RNAP II) through
interactions with the trans-activation responsive element (TAR),
a 59-nucleotide RNA found at the 59 end of all viral transcripts (for
reviews, see [5,6]). Assembly of this complex activates P-TEFb
subunit CDK9 kinase activity [7]. CDK9-mediated phosphoryla-
tion of RNAP II and Spt5 (a subunit of the DRB-sensitivity
inducing factor (DSIF)) directly enhance transcriptional elongation
[8–10] as well as dissociation of repressive NELF factor(s) [11],
allowing more efficient RNAP II promoter clearance. The Tat:P-
TEFb crystal structure, reported by by Tahirov et al. [12], reveals
how these proteins associate and the concomitant conformational
changes this interaction induces in the CycT1:CDK-9 complex.
While P-TEFb is utilized widely for transcription of many genes,
the interaction between Tat and TAR is unique to lentiviruses.
Drugs targeting Tat and/or TAR are expected to both block HIV-
1 replication during the acute phase of HIV-1 infection and to
prevent virus emergence from latency [13]. A variety of candidate
small molecule inhibitors of either HIV transcription, or more
specifically, the Tat-TAR interaction, have been identified during
the last 15 years [9,10,14–19]. Unfortunately none of these
compounds were sufficiently potent and/or selective to progress
beyond phase I clinical trials. Linear polypeptide analogues have
been shown to block the Tat-TAR interaction by binding to TAR
PLoS Pathogens | www.plospathogens.org 1 May 2011 | Volume 7 | Issue 5 | e1002038RNA [16,17,20,21], but their conformational flexibility also
allowed promiscuous binding to host RNAs and non-specific
blocks to viral infectivity [22,23]. Using constrained cyclic
peptidomimetics designed to mimic the antiparallel ß-sheet in
the Tat RNA binding domain we identified a series of competitive
inhibitors of the Tat-TAR interaction with improved affinity and
selectivity compared to the linear peptides [24–27].
In this study, we investigated the antiviral mechanism(s) of these
compounds. Peptidomimetics in this compound series were cell
permeable, had low cytotoxicity, and inhibited viral replication of
a diverse HIV-1 isolate panel in both primary human cells and
immortalized cell lines with low micromolar half-maximal
inhibitory concentration (IC50) values. In contrast to other flexible
linear peptide inhibitors of TAR binding, constrained peptidomi-
metics had no effect on HIV-1 entry [22,23]. Surprisingly,
inhibition of viral transcription did not account for the full
antiviral activity of these compounds. Timed drug addition
experiments then demonstrated that the peptidomimetics have a
dual mechanism of action, blocking both HIV-1 reverse
transcription (an early infection event) and HIV-1 proviral RNA
transcription (a later event).
Results
Inhibition of HIV-1 replication by Tat peptidomimetics
Linear peptide derivatives have been used previously to target
TAR RNA and block Tat binding [16,17,20,21] but their utility
was limited by conformational flexibility which allowed non-
specific RNA binding. To avoid this problem we have developed
conformationally constrained mimics of HIV-1 Tat [24–27] based
on the structure of the BIV (Bovine Immunodeficiency Virus) Tat-
TAR complex [28,29] (Figure 1). Specifically, we constructed a
series of ß-hairpin mimics with 12-residue loops on a heterochiral
D-Pro-L-Pro dipeptide scaffold. This D-Pro-L-Pro scaffold
strongly favors a type-II’ ß-turn backbone conformation, similar
to that found in the Tar RNA binding domain [24–27]. Assayed
in-vitro, several members of this series, L-50, L-51, and L-22,
bound HIV-1 TAR with nanomolar affinity (Kd= 1 ,5 ,a n d
30 nM, respectively) [25,26].
AsshowninFigure2A,thethree TatpeptidomimeticsL-50,L-51
and L-22, were able to inhibit replication of laboratory-adapted
HIV-1 strain NL4-3 (HIV-1NL4-3) in U87 cells expressing the CD4
receptor and CXCR4 coreceptor (U87.CD4.CXCR4 cells). The
relative potency of the compounds correlated with their TAR
binding activity [26]. L-50, which had the highest affinity for TAR,
inhibited HIV-1NL4-3replication with an IC50 value of 4.1 mM,
which was about 10-fold more potent than either L-51 or L-22
(Figure 2B). The activity of L-50 was approximately 10-fold lower
than the licensed antiretroviral drugs 3TC (IC50=0.1260.03 mM
on U87 cells; Figure 2B) as well as Enfuvirtide (IC50=0.1 to 0.5 mM
in U87 cells) [30], a polypeptide retroviral entry inhibitor which
does not require cellular uptake [31].
Cellular uptake
The sequences of the peptidomimetics are derived from the
HIV-1 Tat basic domain (amino acids 48–57) which, in addition
to RNA binding, permits the protein to transverse cellular
membranes [32–35]. Since known cell-penetrating peptides have
flexible structures, we tested whether the constrained peptides
retained cell-penetrating properties. A fluorescein-labeled conju-
gate of polypeptide L-51, prepared by coupling a commercially
available fluorescein-diacetate tag to a hydrazine-derivative of L-
51, was rapidly internalized by living 293T fibroblasts (Figure 2C).
The peptidomimetic accumulated in the nucleus with a
substantial fraction in the nucleoli, resulting from their semblance
to nuclear and nucleolar localization signals [36,37].
Cytotoxicity
L-50 toxicity was compared to that of enfuvirtide (T20), another
anti-HIV-1 inhibitor polypeptide. U87.CD4.CXCR4 cells were
exposed to increasing concentrations of the peptides (maximal of
500 mM) for ten days and cell viability was measured using Alamar
blue staining. Cell viability was similar to control conditions under
all conditions, including the highest L-50 or enfuvirtide concen-
tration tested (500 mM; data not shown), consistent with previous
studies experiments with T20 [31].
Inhibition of multiple HIV-1 clades by the Tat
peptidomimetics
Although pre-clinical development of antiviral drugs typically
involves initial optimization with subtype B laboratory HIV-1
strains, HIV-1 subtypes A, C, D, and CRF01_AE account for over
85% of the global epidemic whereas subtype B comprises less than
10% of present infections [38]. Thus, the long-term utility of any
antiretroviral lies in its ability to inhibit diverse primary HIV-1
isolates of all subtypes - particularly those strains that utilize the
dominant co-receptor (CCR5) for entry. As shown in Figure 2D,
L-50 effectively inhibited a panel of CCR5-tropic and CXCR4-
tropic primary HIV-1 isolates including representatives of subtypes
A, B, C, D, and CRF01_AE (Figure S1A, B). Aside from strain E6-
CRF01_AE, the mean IC50 value for L-50 was 4.7361.33 mM
(Figure 2D). Cross-clade HIV-1 inhibition profiles are important
attributes for potential Tat-TAR inhibitors, since there is
considerable genetic diversity in both the R52 domain of the
Tat protein (Figure 1C) as well as its TAR RNA target sequence in
the HIV-1 LTR (Figure 1D). Furthermore, previous studies using
a linear peptoid Tat-TAR interaction inhibitor in vitro showed
that the principal antiviral activity was due to blocking the
CXCR4 receptor, preventing virus entry rather than viral
transcription [27]. The broad-spectrum of antiviral activity against
multiple clades and viruses that utilize either CCR5 or CXCR4
co-receptors suggests that the constrained peptidomimetics do not
act at viral entry.
Author Summary
The HIV-1 transactivator protein (Tat), together with the
elongation factor P-TEFb binds to an HIV-1 RNA secondary
structure in the 59-UTRs of nascent viral mRNAs (TAR) and
promotes transcription elongation. This process has been
an attractive target for drug development but previous
inhibitors that bind either Tat or TAR have been plagued
by poor inhibition of virus replication, limited cell
penetration, and off-target effects. In this article, we
describe a series of rationally designed cyclic peptides
that block Tat-TAR interactions. L50, the most potent of
these compounds, inhibits a wide range of HIV-1 strains
from around the world. Remarkably, L50 inhibits two
distinct steps in the HIV-1 lifecycle. As expected, L50
inhibits Tat-dependent HIV-1 transcription, but the major-
ity of its anti-HIV activity is due to a block in reverse
transcription, i.e. synthesis of the proviral DNA from the
RNA genome. L50 inhibition of reverse transcription
reveals an important role for TAR RNA during reverse
transcription as well as providing one of first examples of a
drug with a dual mechanism of action.
Tat Peptidomimetic with Dual Inhibition Activity
PLoS Pathogens | www.plospathogens.org 2 May 2011 | Volume 7 | Issue 5 | e1002038Figure 1. The structure and sequence of HIV-1 Tat/TAR RNA. A schematic of the secondary RNA structure of HIV-1 TAR is presented in panel
(A) to describe the relative positioning/interaction with HIV-1 Tat, Cyclin T1, and CDK9. The sites of nucleotide sequence variability among HIV-1
isolates are indicated by the arrows. The bracketed letter or number associated with the polymorphism defines the HIV-1 subtype or circulating
recombinant form, CRF (respectively). (B) The NMR structure of HIV-1 TAR complexed with a small molecule (RBT203) is shown in a space filling model
(PDB file 1UUD in ball-and-stick). (C) Amino acid alignment of the consensus sequences of HIV-1 Tat proteins from all group M HIV-1 subtypes, which
are responsible for the worldwide epidemic. (D) The consensus nucleotide sequence of the HIV-1 TAR RNA element in the various HIV-1 subtypes.
doi:10.1371/journal.ppat.1002038.g001
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inhibition in cell lines but lack potency in primary CD4+ T
lymphoctyes. In the case of L-50, the efficiency of HIV-1NL4-3
inhibition was actually increased in human PBMCs (IC50
0.25 mM) compared to U87.CD4.CXCR4 cells (IC50 4.1 mM)
(Figure 2E).
Figure 2. Testing the susceptibility of HIV-1 to inhibition by Tat peptidomimetics. (A) Comparison of the relative inhibition of the HIV-1
NL4-3 laboratory strain by three lead Tat peptidomimetics. Virus production in cell free supernatant was measured using an endogenous RT assay. (B)
The concentration for 50% inhibition (IC50) of HIV-1 NL4-3 was calculated for the lead Tat peptidomimetics and for the reference antiretroviral, 3TC.
(C) Cell penetration (hT4R5 fibroblasts) and nuclear localization of fluorescein-labeled L-51 peptide analyzed by confocal microscopy. (D) L-50
inhibition of viral replication of three primary CCR5-tropic HIV-1 isolates measured in U87.CD4.CCR5 cells (A1 is the subtype A Rawandan isolate A1-
92RW009, B5 is the subtype B isolate B5-91US056 from the USA and C5 is the subtype C isolate C5-97ZA003 from South Africa) and of CXCR4-tropic
strains (D1 is the Ugandan subtype D isolate D1-92UG021, E6 is the subtype A/E circulating recombinant isolate CRF01_AE from Thailand) as well as
the laboratory strain HIV-1NL4-3 measured in U87.CD4.CXCR4 cell cultures. The IC50 values for L50 and 3TC were calculated from drug susceptibility
curves (Figure S1). (E) Inhibition of HIV NL4-3 was also measure in human peripheral blood mononuclear cells stimulated with PHA/IL-2. The
nucleoside RT inhibitor, 3TC or the non-nucleoside RT inhibitor, nevirapine (NVP) were used as controls. Virus production was measured at 8 and 10
days post-infection by the RT activity in the supernatant (cpm/mL).
doi:10.1371/journal.ppat.1002038.g002
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transcription systems
We next tested whether the peptidomimetics could inhibit Tat
function in a cell-free transcription assay (Figure 3). Cell free
transcription assays have been extensively used in previous studies
of compounds capable of inhibiting Tat [8,15,39,40]. Briefly,
nuclear extracts are incubated with a DNA template harboring the
HIV-1 long terminal repeat (LTR; contains the proviral promoter
and the TAR region) either in the presence or absence of
recombinant Tat protein (Figure 3A). A terminator sequence
inserted downstream of the promoter provides a selective and
effective block to RNAP II elongation in the absence of Tat. As
shown in Figure 3A, transcripts that are unable to traverse the
terminator (labeled t) accumulated in the absence of Tat, whereas
full-length transcript (labeled r) production increased over 20-fold
when Tat was added. Since the levels of short transcripts (t) should
remain unaffected when Tat is inhibited, these transcripts provide
an effective internal control for non-specific inhibition of
transcription. As shown in Figures 3A, addition of increasing
concentrations of the inhibitory peptides L-50 and L-51 decreased
synthesis of full-length transcripts (r) with an IC50 of 50 nM and
500 nM, Under these conditions the production of short
transcripts was largely unaffected. Thus, the Tat peptidomimetics
were potent inhibitors of Tat-mediated transcriptional elongation
in cellular extracts.
Inhibition of transactivation in vivo
In order to evaluate the impact of the Tat peptidomimetics on
HIV-1 transcription in vivo, we used three distinct reporter assay
systems (Figures 3 & 4). First, we measured inhibition of
transcription of stably transfected luciferase reporter genes under
the control of the HIV-1 LTR and a control CMV promoter
(Figure 3B). The addition of Tat increased the levels of the
luciferase reporter gene expression by more than 30-fold in the
case of LTR promoter while the transcription levels of the CMV
promoter remained unaffected (data not shown). Treatment with
10 mM L-50 reduced Tat-mediated transactivation by 53%, but
only reduced transcription from the control CMV promoter by
12% (Figure 3B).
Inhibition of HIV transcription was also measured in a single-
cycle growth assay (Figure 3C). 293T cells were cotransfected with
an infectious molecular clone HIVNL4-3 and a control vector
carrying a luciferase reporter gene downstream of the CMV
promoter. 293T cells support Tat-mediated HIV-1 transcription
and virus production but are resistant to new rounds of virus
production since they lack entry receptors. Addition of 50 mML -
50 peptide inhibited production of the viral RNA by 76% but as
expected for a specific Tat-dependent transcription inhibitor,
CMV promoter-driven luciferase activity reduced by less than 5%
by L-50. Thus, inhibition of HIV-1 transcription by L-50 in both
assays arises from blocks to transcription imposed by a disruption
of the Tat-TAR interaction.
In the third assay, 293T cells were co-transfected with a reporter
plasmid carrying a luciferase reporter downstream of the HIV-1
LTR promoter (pLTR.LUC) alone or in combination with the
Tat-encoding infectious molecular clone HIV-1NL4-3. In control
experiments, cells were co-transfected with a reporter plasmid
carrying the luciferase gene downstream of the CMV promoter
(pCMV.LUC) alone or in combination with HIV-1NL4-3
(Figure 4A). L-50 did not inhibit luciferase expression in cells
transfected with either reporter plasmid alone (Figure 4B). Thus,
although pLTR.luc produces the TAR RNA element as part of
the luciferase mRNA, transcription is not blocked by L-50 in the
absence of Tat. When cells were co-transfected with HIV-1NL4-3,
Tat expression resulted in a ,6.3-fold increase in luciferase
expression. L-50 (200 mM) resulted in a comparatively modest
(1.7-fold), but significant (p=0.03, two-tailed T test, N=5),
decrease in luciferase expression (Figure 4B). As expected, CMV
promoter-driven luciferase expression was not significantly inhib-
ited by L-50.
In addition to measuring luciferase activity, we also measured
viral production to provide an additional measurement of the
antiviral activity of the compounds. It is important to note that,
although luciferase expression is not LTR-driven in cells
transfected by the pCMV.luc control plasmid, HIV-1NL4-3-
encoded virion production is LTR-dependent in both sets of
transfected cells. Treatment with 200 mM L-50 mediated a
modest, but reproducible reduction in HIV-1 virion expression
(Figure 4C). These results were consistent with measurements
wherein L-50 inhibited transcription from LTR-driven cassettes
(Figure 4B). The slightly greater inhibition of virus production
from the pLTR.luc transfected cells by L-50 compared to the
pCMV.luc transfected cells is likely due to competition between
the viral and reporter expression cassettes for limited Tat protein
(Figure 4C).
Thus we were able to demonstrate Tat-mediated transcriptional
inhibition by L-50 in three distinct assays. However, in all these
assays we were only able to detected a 2-fold reduction of RNA or
virus production, which is considerably less than the 10- to 100-
fold HIV-1NL4-3 replication block in the multiple-cycle replication
assays described above. Several possible explanations for this
discrepancy might be: 1) virus released from the transfected cells
were no longer replication-competent, 2) that L-50 has viricidial
activity, or 3) that L-50 inhibited virus replication at additional
steps in the viral life cycle prior to the onset of gene expression.
To test whether the virus released from transfected cells could
be inhibited by L-50 under conditions of multiple-cycle growth,
virus-containing supernatants from 293T transfections (containing
L-50) were used to infect U87.CD4.CXCR4 cells (which support
multiple rounds of HIV-1 replication) and viral progeny were
measured 10 days post-infection. No measurable viral progeny
were produced by viruses which were made in the presence L-50
(Figure 4D). Removal of L50 from virus was attempted by
pelleting virus from supernatant of L50-treated cells transfected
with NL4-3. It is important to note that virus production was
already decreased by L50 at least 50% from transfected cells.
While the results of that experiment (Figure 4D) imply that L-50
inhibits viral egress through the target cells at some event prior to
viral transcription, those data could not rule out virucidal activity.
A cell-free preparation of HIV-1NL4-3 virions was incubated for
2 h with or without L-50 (50 mM or 500 mM). After pelleting virus
to remove drug, we found similar viral infectivity with and without
L-50 treatment suggesting that this drug was not a viricide (Figure
S2). The strong implication of this experiment is that L-50
inhibited HIV replication by another mechanism during the
replication cycle.
Time-dependent drug addition kinetics
The preceding experiments show that, although L-50 weakly
inhibits HIV transcription in vivo, this activity does not account for
the majority of its antiviral activity. To identify the key step(s) in
the virus replication cycle that are inhibited by L-50, time-of-drug-
inhibition experiments were performed (Figure 5). For each
measurement, virus was added to cells at time 0 and HIV-1 gene
expression (based on luciferase expression) was assayed at 72 h
post infection. The HIV-1NL4-3virus employed in the experiment
shown in Figure 5 carried the firefly luciferase gene inserted
between the env and nef genes [41]. Luciferase expression was
Tat Peptidomimetic with Dual Inhibition Activity
PLoS Pathogens | www.plospathogens.org 5 May 2011 | Volume 7 | Issue 5 | e1002038Figure 3. L50 inhibition of Tat-dependent transactivation in cell-free, reconstituted transcription system and in transfected cells.
DNA templates carrying the HIV promoter were transcribed in the presence or absence of recombinant Tat protein (+Tat) and increasing
concentrations of the Tat peptidomimenic (L-50, left panel; L-51, right panel) (A); r identifies full-length transcripts and t identifies transcripts ending
at the terminator sequence inserted proximal to the promoter. Relative transcription levels of the Tat-dependent full-length transcript r decreased by
4-fold with the Tat peptidomimetic while the Tat-independent t product remained almost unaffected. (B) 293T cells were transfected with the
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as a readout for viral replication. Comparable results were
obtained in experiments when virus production was measured
by RT activity (data not shown). Virus replication was limited to a
single round by the addition of the HIV-1 protease inhibitor
saquinavir, at 2 h post infection in each experiment.
The time of addition assay was calibrated using HIV inhibitors
which selectively inhibit distinct steps in the viral replication cycle
(Figure 5A). All drugs were added at intervals and, as the infection
progressed, each drug became ineffective at a time consistent with
the completion of their targeted infection event (Figure 5B).
Additions of AMD3100, a CXCR4 antagonist which prevents
HIV-1 co-receptor attachment, became ineffective very soon after
infection (t1/2=0.77 h; Figure 5B & C). The viral fusion inhibitor
Enfuvirtide (or T20) remained effective at slightly later additions
(t1/2=1.0 h), consistent with a fusion event occurring after
receptor binding. Inhibition by 3TC is slowly lost over 12 h (t1/2
=6.6 h; Figure 5D), i.e. throughout the time required to complete
reverse transcription (Figure 5B), consistent with previous results
for this drug [42].
The integration inhibitor Raltegravir and the transcription
inhibitor 5,6-dichloro-1-ß-D-ribobenzimidazole (DRB), blocked
HIV-1 replication with significantly delayed kinetics compared to
the entry and reverse transcription inhibitors (Raltegravir t1/2
=11.5 h; DRB t1/2=31.1 h; Figure 5B & D). It is worth noting
that data with DRB, which is a potent inhibitor of the CDK9
subunit of P-TEFb, can be considered to behave analogously to a
potential Tat inhbititor, since P-TEFb is strictly required for Tat-
dependent HIV transcription [43,44].
When L-50 was added either prior to infection or at various
time points following infection (every 30 minutes for the first 2 h,
every hour for the next 13 hours, and then every 3–6 hours
thereafter), we observed an unusual, biphasic inhibition profile
over the 72 hour time course (Figure 5B). There was an initial
inhibitory phase at approximately 2 h post infection (t1/2=1.8 h)
when L-50 was able to block nearly 100% of viral replication.
Thus, L-50 inhibits a step immediately following virus entry within
the time window of the first stages of HIV-1 reverse transcription.
When L-50 was added during the next 20 hours (t1/2 of 35.7 h),
i.e. during the period after reverse transcription and subsequent to
completion of proviral integration, there was a second phase of
viral inhibition. The timing of this second phase was similar to the
inhibitory kinetics of transcription inhibitor DRB (35.3 h;
Figure 5E). Thus, L-50 blocks both an early post-entry step
during HIV-1 replication as well as Tat-mediated transactivation
of HIV-1 transcription.
L-50 does not block HIV-1 entry
The kinetic experiments shown in Figure 5, demonstrated that
L-50 primarily inhibits HIV-1 replication at a step immediately
following entry (t1/2=1.8 h) but prior to the inhibition of reverse
transcription by 3TC (t1/2=6.6 h). The timing of these events is
consistent with L-50 inhibiting either a very early step in reverse
transcription or an entry step following formation of the gp41 pre-
hairpin intermediate, i.e. the Enfuvirtide-sensitive state, prior to
cell-viral membrane mixing and pore formation. To distinguish
between these two possibilities, we performed a second time-of-
drug inhibition experiment using cell-to-cell fusion to introduce
Tat and activate an already integrated provirus (Figure 6A). In this
assay, effector 293T cells were transfected with pREC.NFL, a
CMV-driven expression plasmid carrying an HIV-1 provirus and
lacks the HIV-1 59-LTR sequence [45]. Transcription of the
proviral construct produces all the HIV-1 proteins, including the
gp120-gp41 envelope glycoprotein, which is expressed on the cell
membrane and is required to induce cell fusion with the
U87.CD4.CXCR4 target cells. Since the pREC.NFL vector lacks
a59-LTR, none of the transcripts produced in the effector cells can
serve as templates for reverse transcription [45]. The
U87.CD4.CXCR4 target cells were transfected with pDM128-
LTR-fluc2 (see Materials and Methods) to provide a Tat- and
Rev-dependent reporter. After fusion of the two cells, the HIV-1
Tat (and Rev) proteins migrate into the nucleus of the target cell,
and stimulate luciferase production (Figure 6A). Thus, this assay is
sensitive to inhibitors of membrane fusion and viral entry and
inhibitors of viral transcription, but insensitive to inhibitors of
reverse transcription.
Cell-to-cell fusion was initiated by pelleting the transfected
293T cells on to monolayers of U87.CD4.CXCR4 cells at 4uC.
The drugs (L-50, 3TC, or DRB) to be tested were added at
various time points, similar to the timed-drug-addition experi-
ment described above (Figure 6A). Tat/Rev-dependent luciferase
expression was measured in the cell lysates 72 h post fusion. This
cell-to-cell fusion assay is highly sensitive to inhibition by both
T20 and AMD3100 (data not shown) indicating that cell-to-cell
fusion is both receptor-dependent and mechanistically identical to
HIV-1 entry into a cell [46]. Because cell-to-cell fusion is not
followed by reverse transcription or integration, 3TC was unable
to inhibit reporter gene activation at any time (Figure 6B). In
contrast to the time-of-drug addition experiment using free virus
(Figure 5), L-50 exhibited a monophasic inhibition profile, with
t1/2 of 8.2 h, similar to that exhibited by CDK-9 inhibitor DRB
(t1/2=11.3 h; Figure 6B). Thus, this experiment provides strong
and direct evidence that L50 does not inhibit the HIV-1 entry
process and blocks Tat-dependent HIV-1 transcription, in
contrast to the previously studied linear peptides derived from
Tat [22,23].
Inhibition of reverse transcription by L50 is independent
of its effects on HIV transcription
In the experiment shown in Figure 6, we studied the late phase
of L-50-mediated antiviral activity using an assay that was
dependent on the Tat-TAR interaction but not on reverse
transcription. To study the impact of L-50-on reverse transcription
alone, we devised an assay that does not require HIV-1-dependent
transcription for the readout (Figure 7A). For this experiment, we
utilized an HIV-1 expression construct in which the env gene was
replaced by a luciferase gene expressed under the control of the
SV40 promoter (pNL.Luc.AM [47]). Using this reporter system,
luciferase expression became dependent upon early infection
events (i.e. entry, reverse transcription, integration), but the
transcription of the reporter itself was independent of Tat-
mediated transcriptional enhancement.
plasmids pLTR-luc (LTR) + Tat or pcDNA.LUC (CMV), where the luciferase gene was under the control of the HIV-1 LTR or CMV promoters, respectively.
Cells were treated with either 2 or 10 mM L50. Relative light units, based on luciferase expression, were reported as percentages of the no drug
controls. (C) L-50 was added to 293T cells transfected infectious molecular clone (pNL4-3) while expression of 293T cells transfected with luciferase
reporter provided the control. Virus production from the 293T cells transfected with pNL4-3 was monitored by RT activity and expressed as a percent
transcription.
doi:10.1371/journal.ppat.1002038.g003
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ing the pNL-Luc.AM vector with pSM.WT which expresses the
HIV-1HXB2 env glycoproteins [47]. As shown in Figure 7A, L-50
efficiently blocked luciferase expression in HIV-1Luc-AM infected
cells. As positive controls, both DRB and 3TC also efficiently
inhibited luciferase expression from HIV-1Luc-AM. These findings
are again consistent with a model in which L-50 blocks HIV-1
reverse transcription by binding TAR RNA.
L-50 does not inhibit MLV reverse transcription
Reverse transcription inhibitors, such as nucleoside analogues
AZT, 3TC and ddI, generally block replication of all retroviruses
Figure 4. L50 effects on Tat-mediated transactivation of mRNA transcription in cell lines. (A) A schematic of the dual transfection of
pNL4-3 and pcDNA.LUC (CMV) or pLTR-luc in 293T cells. Luciferase (in lysates) (B) and RT activity (in cell-free supernatants) (C) was measured 72 h
following transfection/drug treatment of 293T cells. Supernatant from 293T transfections conditions were used to infect U87.CD4.CXCR4 cells. (D)
Virus production at 10 days post infection was measured by RT activity.
doi:10.1371/journal.ppat.1002038.g004
Figure 5. Time-of-drug-addition experiment during synchronized HIV-1 infections. Panel (A) provides a schematic representation of the
experimental protocol, including the spinoculation step for synchronized virus infection and timing of drug additions over the 72 h time course. The
relative time frame associated with each retroviral step is defined based on the time frame of sensitivity to the drug that blocks that particular
replication step. Panel (B) plots the level of inhibition mediated by a specific drug added at a specific time post infection. Virus production, regardless
of the timing of drug addition, was measured by luciferase activity at 72 h post infection. Curves are fitted to % inhibition mediated by the timed
addition of each drug. Inhibition by a drug is absent after the completion of the specific step known to be a target of that drug. For example,
AMD3100 bind CXCR4 and prevents HIV-1 entry; thus, inhibition of HIV-1 by AMD3100 is not observed if the drug is added .2 h post infection, i.e.
after the HIV-1 entry step is complete. A biphasic curve was fitted to inhibition mediated by timed addition of L50. The first 12 hours of the timed
drug addition was magnified to examine the inhibition of HIV-1 entry and reverse transcription (panel C; early events). These early steps of HIV-1
replication were removed from the plots in panel D (late events) to focus on the timed inhibition by integration and transcription inhibitors. The
times of drug addition that maintains 50% inhibition (t1/2) are shown for each drug in the insets. All time-of-drug-inhibition experiments were
performed in triplicate which resulted in a 10–15% variance in the inhibition levels. Error bars are not shown to prevent figure congestion.
doi:10.1371/journal.ppat.1002038.g005
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inhibitors, such as nevirapine and efavirenz, specifically bind to
HIV-1 RT and not to polymerases from other lentiviruses or
retroviruses [48]. Thus, it is possible that L-50, binds non-
specifically to RNA structures present in other retroviruses.
However, as shown in Figure 7B, L-50 (250 mM) did not inhibit
murine leukemia virus (MLV) whereas AZT (100 mM) completely
blocked MLV replication. These data suggest that L-50 is not a
general inhibitor of retroviral reverse transcription, but is specific
for the HIV-1 TAR RNA sequence and/or HIV-1 reverse
transcriptase.
L-50 blocks HIV-1 reverse transcription in vitro
To test directly whether L-50 is able to inhibit HIV-1 reverse
transcription, we used an in vitro assay reconstituting HIV-1
reverse transcription. This assay measures the synthesis of (-)
strand strong stop DNA by recombinant HIV-1 RT (p66/p51)
from an 18 nt DNA primer, pre-annealed to an HIV-1 RNA
template encompassing the repeat (R), 59 unique sequence (U5),
Figure 6. Time-of-drug-addition experiments during synchro-
nized cell-to-cell fusion. (A) A cell-to-cell fusion was mediated by an
effector 293T cell, expressing HIV-1 Env gp120/gp41 (via pREC nfl
transfection), binding to CD4 and CXCR4 receptors on a target U87 cell.
The luciferase reporter is only expressed after HIV-1 Tat and Rev migrate
from the effector cytoplasm to the target nucleus in the fused cell and
transactivates/rescues LTR-driven mRNA expression. (B) The timing of
3TC, DRB, and L50 inhibition was measure in this synchronized cell-to-
cell fusion where a smaller number of transfected 293T cells are
pelleted onto adherent U87.CD4.CXCR4 cells. Luciferase expression is
measure 48 h post cell fusion. The times of drug addition that maintains
50% inhibition (t1/2) are shown for each drug in the insets. Triplicate
measurements resulted in a 10–15% variance in the inhibition levels.
doi:10.1371/journal.ppat.1002038.g006
Figure 7. L50 effects on HIV-1 and MLV reverse transcription
during cell culture infections. (A) HIV-1 Luc-AM has the luciferase
gene under the control of the SV40 promoter within the HIV-1 genome
and in place of the deleted HIV-1 env gene. This virus, pseudotyped
with exogenous HIV-1 Env expression, as used to infect U87.CD4.CXCR4
cells in the absence of drugs or in the presence of L-50, DRB, or 3TC. (B)
MLV, harboring a GFP gene and pseudotyped with VSV-G Envelope
glycoprotein, was used to infect 293T cells in the absence of drugs or in
the presence of L-50 or AZT.
doi:10.1371/journal.ppat.1002038.g007
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increasing concentrations of L-50 strongly inhibited (2) strand
strong stop DNA with an IC50 value of 5.560.57 mM (Figure 8A
and B). This inhibitory concentration is only slightly greater than
the RNA template concentration in the reaction mixture (,2 mM)
consistent with the very tight affinity of L-50 for TAR RNA [26].
To determine if L-50 inhibition of reverse transcription was
dependent on the high affinity Tat-binding site located at the TAR
bulge, mutations that inactivate Tat-binding were introduced into
the RNA template (Figure 9A). As expected, L-50 was less potent
at inhibiting the (2) strand strong stop DNA on the mutant TAR
RNA template (Figure 9B and C). For example, 8 mM L-50
inhibited 80% of (2) strong stop synthesis on the wild type
template but the same drug concentration inhibited less than 10%
of (2) strong stop DNA synthesis on a template with mutations in
the TAR L-50 binding site.
Discussion
Design of peptidomimetic inhibitors with high affinity for
TAR RNA
The Tat-TAR complex has long been the focus of drug discovery
efforts because of its central and unique role in regulating HIV-1
transcription. Unfortunately, previousattempts to discover a potent,
specific and stable anti-Tat-TAR compound with efficient cellular
uptake have been unsuccessful. The majority of the efforts to design
Tat inhibitors involved highly charged cationic drugs [14,15,21,50–
52], oligonucleotide analogues with poor bioavailability [53,54], or
proteolytically stable peptoids [16,17] and oligo-carbamates [55].
These compounds were abandoned due to their comparatively non-
specific interactions with RNA. Other lead molecules, such as
ALX40-4C [18,22,56]and CGP64222 [17], wereinitially identified
as Tat-inhibitors and progressed to early clinical studies but were
withdrawn from further pharmaceutical development after their
antiviral activity was identified as cell surface receptor ligands.
Our design of inhibitors of the TAR RNA-Tat protein interaction
started with the assumption that constrained peptidomimetics would
provide effective rationale to block the relatively large interfaces
formed between the viral protein and its cognate RNA [24–27]. The
D-Pro-L-Pro template restricts pharmacophores into planar ß-
hairpin structures with side chains emerging from each side. Several
lead peptides, including L-20, L-50, and L-51 had nanomolar
affinities for HIV-1 TAR and effectively discriminated against the
analogous BIV TAR RNA sequence. Specific and high affinity
binding allowed these compounds to compete with Tat protein and
displace it from preformed complexes with TAR in vitro.T h i sp o t e n t
inhibition of Tat is remarkable considering the 3-fold reduced size of
the peptidomimetics compared to the protein [25].
NMR structures of the peptide-RNA complexes revealed that
Tat peptidomimetics bind in the major groove near the UCU
bulge, which forms an essential part of the Tat binding site, and
induce specific conformational changes that are similar to those
seen with Tat [27]. Specifically, the constrained Arg residues at
positions 3 and 5 of the cyclic peptide structures are located near
the bulge region of TAR RNA. The pharmacophore ‘‘locking’’
exemplified for these two critical residues leads to remarkable
specificity in binding to TAR RNA. The larger peptidomimetics
show enhanced affinity due to specific interactions with the TAR
RNA apical loop sequence [26].
Cyclic peptidomimetics are potent inhibitors of HIV-1
replication
The three lead Tat peptidomimetics (L-20, L-50, and L-51) are
potent inhibitors of HIV-1 replication. The lead molecule L-50
inhibits HIV-1 in primary human lymphocytes in the same
concentration range as do the FDA-approved small molecule
inhibitors nevirapine and 3TC. Additionally, these Tat peptido-
mimetics were not cytotoxic and did not inhibit cell growth up to
1 mM.
Direct addition of the peptidomimetics to cultured cells blocked
HIV-1 replication, without requiring a carrier molecule to
facilitate drug diffusion across plasma membranes. In contrast to
previously characterized flexible peptides, which selectively
inhibited HIV-1 replication by binding to the CXCR4 receptor
[22,23], L-50 inhibited a panel of both CXCR4- and CCR5-using
primary HIV-1 isolates, representing the major subtypes currently
circulating (A, B, C, D, and CRF01_AE). This data was satisfying
because it implied that L-50 recognized conserved RNA secondary
structure elements in TAR RNA even though the nucleotide
sequence in this region varies considerably between strains
(Figure 1D).
Inhibition of multiple steps in the HIV-1 life cycle by the
peptidomimetics
We demonstrated that the peptidomimetic L-50 inhibited Tat-
mediated HIV-1 transcription using both cell free transcription
assays and multiple independent in vivo assays using cell lines
carrying reporter genes and integrated HIV-1 proviruses. In all of
these assays, L-50 induced an approximately two-fold reduction in
HIV-1 transcription, which was much less than the 10- to 100-fold
reduction in HIV-1 replication we observed in viral replication
assays. Using a variety of HIV-1 inhibitors in a time-of-drug-
addition experiment we identified two specific steps in the HIV-1
lifecycle that were inhibited by L-50. As expected, L-50 was
identified as an inhibitor of HIV-1 transcription since it block viral
replication with a time course that closely resembled the DRB, a
drug which prevents RNAP II transcriptional elongation by
selectively inhibiting the protein kinase component of P-TEFb,
CDK9 [43]. Additionally, L-50 inhibited an early event in HIV-1
replication. L-50 retained antiviral activity after entry inhibitor
Enfuvirtide became ineffective (t1/2=1.07 h), but lost some
activity (L-50 t1/2=1.8 h) approximately 4.8 hours before nucle-
oside RT inhibitor 3TC (t1/2=6.6 h) lost activity.
To rule out non-specific HIV-1 entry inhibition, such as had
been observed for linear Tat-derived peptidomimetic inhibitors
[22,23], we used a cell-to-cell fusion assay which is not dependent
upon reverse transcription or integration but faithfully mimics the
mechanism of virus-to-cell binding, fusion [31] and Tat-dependent
transcription (of the luciferase reporter). L-50 inhibition kinetics
again coincided with DRB inhibition but there was no measurable
inhibition of cell-to-cell fusion by the compound.
Inhibition of HIV-1 reverse transcription
Both Tat and TAR RNA are thought to play an important role
in HIV-1 reverse transcription [57–60]. TAR is a structure
derived from the repeat (R) and 59 unique sequence (U5) of the
LTR, and located just upstream of the primer binding site (PBS),
the initiation site of reverse transcription. There is evidence that
TAR RNA structure contributes to the HIV-1 reverse transcrip-
tion process [49,61–64] by participating in a larger tertiary RNA
secondary structure necessary for the efficient initiation of reverse
transcription from tRNA
Lys,3 [65,66]. Nucleocapsid-mediated
TAR RNA unwinding may also prevent self-priming and/or
coordinate RNase H activity to free the end of single-stranded,
minus strong-stop DNA. This strong-stop DNA product (comple-
ment of R and U5 RNA sequences) could then pair with the 39 R
region of RNA, adjacent to the U3 sequence, thereby facilitating
the first template switch and eventual completion of minus DNA
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also facilitated by the nucleocapsid protein (NC) chaperone
activity [67]. Deleting or mutating TAR RNA reduces first
template switch efficiency [49] and mutations that increase the
stability of TAR RNA appear to block strand transfer [68].
There is also evidence that Tat plays a role in viral reverse
transcription, although much of this work has been controversial.
Loss of function Tat mutants have been reported to impair reverse
transcription 3- to 5-fold compared to wild type HIV-1 both in
infected T cells and in endogeneous reverse transcription reactions
[58,69]. Tat-mediated RNA secondary structure remodeling may
facilitate obligatory strand transfers during viral DNA synthesis by
reverse transcriptase [60]. However, it is possible to create
replication-competent viruses where the TAR RNA sequence is
replaced by a short hairpin RNA structure suggesting that Tat is
dispensible for reverse transcription [70]. Our kinetic studies
demonstrate that the first phase of L-50 inhibition corresponds to
reverse transcriptional initiation. HIV-1 reverse transcriptase
encounters the TAR stem-loop within the first ,150 nt of minus
strong-stop DNA synthesis, so the L-50-TAR RNA complex might
disrupt HIV-1 reverse transcription initiation, prevent elongation
or block the first template switch. Synthesis of the proviral genome
(nearly 20,000 nucleotides) is thought to occur within the first
12 hours of infection, consistent with the t1/2 (6.6 h) we measured
for 3TC (and ,7 h reported for non-nucleoside RT inhibitor
nevirapine [42]). It is then not surprising that nucleoside RT
inhibitor 3TC, which blocks polymerization opposite any
guanosine/deoxyguanosine base during this process, exhibits
prolonged activity compared to L-50. Thus, inhibition during
minus-strand strong stop DNA synthesis would likely occur
immediately following entry (,1 hrs), within the first few minutes
of reverse transcription, accounting for the narrow window of L-50
efficacy in the first phase (1.8 h). AZT and 3TC blocked MLV
replication whereas L-50 did not, confirming that L-50 activity is
specific to HIV-1. The exact inhibitory mechanism exerted by L-
50 on HIV-1 reverse transcription is the subject of ongoing studies.
The data presented in Figure 8 provides in vitro evidence that L-
50 blocks (2) strand strong stop DNA synthesis in a TAR-
dependent manner. However, we have not ruled out additional
effects of L-50 on reverse transcription, including (1) disruption of
tRNA
Lys,3 binding to HIV-1 RNA, (2) inhibition of a transition
from tRNA
Lys,3 initiation (+1t o+5 nt) to (2) strong-stop DNA
elongation, (3) block in proper RNase H digestion of 59 LTR
RNA, and finally, (4) prevention of the first strand switch necessary
to complete (2) strand DNA synthesis.
Conclusions
We have shown that cyclic peptidomimetics derived from HIV-
1 Tat are potent inhibitors of HIV-1 replication. Detailed
characterization of the L-50 mechanism of action revealed that
it is able to inhibit two important steps in the virus life cycle that
involve TAR RNA: HIV-1 reverse transcription and Tat-
mediated transcription. Although L-50 was more potent at
inhibiting HIV-1 reverse transcription (IC50=1 to 10 mM) than
HIV-1 mRNA transcription (IC50 .100 mM), this difference in
Figure 8. Inhibition of minus strand strong stop DNA synthesis
by L50. (A) A reconstituted in vitro reverse transcription assay was
performed with increasing L50 concentrations to determine the level of
inhibition during (2) strand strong stop DNA synthesis. Quantitation
using a phosphorimager was performed on full length (2) strand strong
stop DNA products (full ssDNA; red box) as well as two intermediate
paused DNA products (intermediate paused ssDNA; blue and green)
and then plotted in panel (B). All experiments were performed in
triplicate to calculate the L50 IC50 concentration (5.560.57 mM) to
inhibit (2) strand DNA synthesis. IC50 values were identical for all three
(2) ssDNA products.
doi:10.1371/journal.ppat.1002038.g008
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PLoS Pathogens | www.plospathogens.org 12 May 2011 | Volume 7 | Issue 5 | e1002038Figure 9. Minus strand strong stop DNA synthesis from wild type or mutant. (A) Schematic representation of HIV-1 RNA fragments
representing the R, U5, and primer binding sequence (PBS) in wild type (wt_R_u5_pbs), site-directed mutagenesis of the TAR bulge (mutant TAR), or
Tat Peptidomimetic with Dual Inhibition Activity
PLoS Pathogens | www.plospathogens.org 13 May 2011 | Volume 7 | Issue 5 | e1002038potency might simply reflect the stoichometry necessary for
inhibition. Relatively few virions enter a cell to establish infection
which dramatically limits the number of TAR RNA sequences
that need to be bound by L-50 (in theory, infection can be initiated
by a single virion carrying only two viral genomes). By contrast,
there are several thousand rounds of HIV-1 RNA transcripts
produced during the later stages of the virus life cycle and each
transcript carries TAR RNA as part of its leader sequence. Our
unexpected discovery that L-50 has a dual inhibitory mechanism
demonstrates that drugs can be designed that simultaneously
inhibit reverse transcription and HIV-1 transcription by targeting
the highly conserved TAR RNA element.
Methods
Peptide synthesis
The ADP-1 peptide containing the entire RNA-binding activity
of Tat protein [71] was prepared on MBHA-Rink amide resin
using Fmoc-chemistry on an Applied Biosystems 433A peptide
synthesizer. The synthesis of the cyclic peptides has been described
previously [25]. Peptide L-51 conjugated to a fluorescent dye was
produced by coupling of commercially available 5(6)-carboxy-
fluorescein diacetate to an analogue of L-51, containing D-trans-4-
hydrazinoproline (Hyd) in place of D-Proline (i.e. cyclo-(Arg-Thr-
Arg-Thr-Arg-Gly-Lys-Arg-Arg-Ile-Arg-Val-Hyd-Pro).
Inhibition of Tat-dependent transactivation in cell-free
transcription reactions
Plasmids carrying the wild type HIV-1 LTR [71] were
linearized with XbaI and biotinylated at both the 59 and 39 ends
by incorporation of biotin-16-dUTP (Roche) [72]. In order to
form the elongation complexes, the DNA was linearized,
biotinylated and immobilized on streptavidin-coated magnetic
beads (Dynal) that were added to the reaction mixtures as
described [8]. Twenty ng of Tat protein were added and the
elongation-competent complexes were assayed at increasing
concentration of peptidomimetic inhibitors (usually from 0.1 to
20 mM). The reaction mixtures were incubated for 20 min at 30uC
with occasional mixing and analyzed by fractionation of 6%
polyacrylamide gels [8].
Microscopy
Human fibroblasts or HeLa cells (56104) were plated on
35 mm glass bottom culture dishes in DMEM/10% FBS (Gibco,
Invitrogen) and cultured for 12 to 48 hours to obtain a confluency
of 40-60%. The medium was discarded and cells were washed
with PBS followed by incubation with media containing 3 mM
fluorescent L-51 at 37uC for 10 min. After incubation with the
fluorescent peptide, the medium was discarded and the cells were
washed five times with PBS and a final volume of PBS was added
for observation of living cells. Cells were imaged at 406
magnification using an Olympus IX70 epifluorescent inverted
microscope. Cell observation was done with a Delta Vision RT
dencovolution system and images were captured using a CCD
digital camera. Scattered light was computationally reassigned
using Softworx software (Applied Precision Inc.).
Plasmids
Several previously reported eukaryotic expressioin constructs
were used for this study. Plasmid pNL4.3 was originally reported
by Adachi et al. [73] Plasmids pLTR.luc and pCMV.luc contains
an HIV-1 LTR or CMV promoter cloned upstream of the firefly
luciferase gene, respectively [74]. pDM128-LTR-fluc2 (a gift from
David McDonald [75]) was produced by replacing the SV40
promoter with the HIV-1 LTR and replacing the exonic CAT
coding sequence with the firefly luciferase gene. The resulting
plasmid expresses firefly luciferase when the Tat dependent, LTR-
driven unspliced RNA transcript is rescued by HIV-1 Rev.
Plasmid pNL.luc.AM (a gift from Andre Marozsan [47]) is an
HIV-1 expression construct wherein the Env ORF has been
interrupted by an in-frame stop codon followed by SV40-
promoted luciferase ORF. This construct produces luciferase
constitutively in the transfected cells and, when co-expressed with
a viral envelope supplied in trans, in target cells which have been
infected by the resulting VLPs. Pseudotyped virus was produced
using HIV-1 Env expression plasmid pSM.WT described
elsewhere [76]. pREC-nfl (or pREC nfl_HIV-1) was cloned as
previously described and lacks the 59LTR of proviral NL4-3 DNA
[45]. The near full length genomic (nfl) RNA is expressed from the
CMV promoter and is spliced into all HIV-1 mRNA products to
produce the full complement of HIV-1 proteins. The vector
supports HIV-1 Env glycoprotein expression and cell fusion with
U87.CD4.CXCR4 cells. The vector also produces virus particle
that can de novo enter a susceptible cell but the core is incapable
of supporting reverse transcription [45].
Cells and viruses
U87.CD4.CXCR4/CCR5 cells were obtained through the
AIDS Research and Reference Reagent Program and were
maintained in DMEM (Mediatech, Inc., Herndon, PA) supple-
mented FBS medium (15%, Life Technologies, Inc., Rockville,
MD), penicillin/streptomycin, G418 and puromycin. 293T cells
were maintained in DMEM supplemented with 10% FBS and
pen/strep. PBMC from HIV-seronegative donors were prepared
as previously described [77]. The pNL4-3 infectious molecular
clone was obtained through the AIDS Research and Reference
Reagent Program. Infectious virus was produced and titered as
previously described [77].
Inhibition of Tat-dependent transactivation
293T cells were incubated with peptidomimetics and co-
transfected with various combinations of pNL4-3 – an infectious
molecular clone, pLTR.luc - a vector with the luciferase gene
under control of the HIV-1 LTR, and pcDNA.LUC - a control
plasmid expressing luciferase under control of the CMV promoter.
Cells were transfected using a lipofectamine protocol as previously
described [45]. Cell-free supernatant was collected 24 h post-
transfection and assessed for RT activity, while the cells were lysed
and assessed for luciferase activity. To assess inhibitor effects on
integrated proviruses, 293T cells containing a Tat-deficient LTR
reporter were pretreated with the peptides for 1 h and transfected
with a Tat-expressing plasmid. The cells were incubated for 24 h,
lysed, and assessed for luciferase activity.
truncated template lacking the majority of the R region. (B) Minus strand DNA products catalyzed by HIV-1 RT (p66/p51) and extended from an end
labelled 18 nt primer binding to the pbs. The products were resolved on an 8% denaturing PAG. (C) Plot of the (2) strand strong-stop DNA product
produced on the various RNA templates. Bands on the gel were quantified using a phosphorimager.
doi:10.1371/journal.ppat.1002038.g009
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Drug sensitivity assays were performed on U87.CD4.CXCR4/
CCR5 cells and in peripheral blood mononuclear cells (PBMC).
Peptidomimetics or control drugs were added to cells to yield final
concentrations between 100 mM and 10 nM. Cells were incubated
with drug for 1 h and exposed to the virus at a multiplicity of
infection of 0.001, incubated with the virus for 24 h, and input
virus washed away. Supernatant aliquots were removed and virus
production was quantified by reverse transcriptase assay [77].
Virus production at each drug concentration was normalized and
the relative values were plotted versus drug concentration to
determine 50% inhibitory concentrations (IC50). Variations on
these drug susceptibility assays are defined in each figure and
related text. For the time-of-drug-inhibition experiments, HIV-1
was spinonculated onto U87-CD4/CCR5 cells as previously
described [42]. The cells were washed twice with cold phosphate
buffered saline (PBS) to remove unbound virions. Cells were
resuspended in cold medium and split into 96-well plates (50 ml/
well). Virus-cell mixes were synchronized for entry by addition of
130 mlo f3 7 uC medium, and then AMD3100 (10 mM), Enfuvir-
tide/T20 (10 mM), Lamivudine/3TC (100 mM), Raltegravir
(10 mM), DRB (50 mM), and L50 (250 mM) was added at one of
the various time points post synchronized infection (described in
Figure 5) and maintained up to 72 h. Cells were incubated for
72 h and then treated with lysis buffer and luciferase activity was
determined. The same procedure was utilized for the time-of-
drug-addition experiment involving cell-to-cell fusion. However, in
these analyses, 293T cells were transfected with pREC.nfl [45] and
then added (like virus as the method above) to the
U87.CD4.CXCR4 target cells. Cell-to-cell fusion was initiated
by removing cold medium and adding 37uC medium.
In vitro reverse transcription assays
HIV-1 RNA representing the wild type R, U5, pbs, and
uncoding sequence (270 nt) (wt R_U5_pbs RNA) was produced by
in vitro T3 transcription (T3 MegaScript, Ambion) from a PCR
product (with T3 extended primer) derived from NL4-3. The
deleted R region transcript (DR_U5_pbs RNA) was produced
using the same in vitro transcription method but from a truncated
PCR production (i.e. lacking 41 nt of R region). The mutant TAR
RNA transcript (with mutations 59-UCUG-39 to 59-UGGU-39 in
the bulge) was generated by T3 transcription from a PCR product
with the forward primer having the nt substitutions for site-
directed mutagenesis. The primer sequences for PCR are available
upon request. The DNA primer (18 nt), complementary to the
primer binding sequence (39 end of tRNA
Lys,3), was annealed to
the template as described [78]. The DNA primer was annealed to
the various HIV-1 RNA templates by denaturation and annealing
conditions previously described [78]. The primer:template an-
nealed mixture (approximately 0.5 and 0.25 pmols) was added to
20 ml reaction mixture containing 50 ng of HIV-1 RT [49,78] and
in the absence or presence of L50 (0.002 to 66 mM). Reactions
were incubated at 37uC for 45 min and then quenched with
formamide EDTA loading buffer [78] for subsequent electropho-
resis on a 8% denaturing polyacrylamide gel. Gels were
autoradiographed and analyzed with a BioRad phosphorimager.
The full length (2) strand strong stop DNA product is 181 nt on
the HIV-1 wt_R_U5_pbs or mutant TAR RNA templates and
140 nt on the DR_U5_pbs RNA template.
Supporting Information
Figure S1 Susceptibility of CCR5 and CXCR4-using HIV-1
isolates to L50 in either U87.CD4.CCR5 (A) or U87.CD4.CXCR4
(B) cells, respectively. The assays are described in Figure 2 of the
manuscript.
(EPS)
Figure S2 Infectivity of virus treated with L50. To test the
possibility that inhibition of HIV replication by L-50 is due to
direct interaction of the compound with viral particles, cell-free
NL4-3 HIV-1 was incubated for 2 h with or without L-50 (50 or
500 mM). After pelleting virus at 30,000g for 1 h to remove drug,
NL4-3 was resuspended in 1x RPMI and used to infect
U87.CD.CXCR4 cells. Cell-free supernatant was removed at
day 6 to measure RT activity. The graph plots RT activity relative
to the no drug control.
(EPS)
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